CTRI/2023/11/060206尚未招募4 期
The efficacy and safety of Imeglimin versus standard of care in Type 2 Diabetes Mellitus patients not controlled on metformin monotherapy, A Randomized controlled trial. - NI
Dr Raj Kamal0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Type 2 Diabetes Mellitus patients not controlled on Metformin monotherapy
- •2. Glycemic control with Hba1c range of > 7.5 and <8 %
- •3. FBS >126 and <160
- •4. Type 2 Diabetes Mellitus patients of both genders
- •5. Type 2 Diabetes Mellitus patients of BMI <22.9 kg/m2
- •6. Type 2 Diabetes Mellitus patients with written informed consent
排除标准
- •1. Type 1 Diabetes Mellitus
- •2. Gestational Diabetes Mellitus
- •3. Liver failure and Renal failure
- •4. Patients with MIcro and Macro vascular complications
- •5. Patients with Inflammatory Bowel disease
- •6. Anaemic patients
- •7. Patients not willing to give informed consent
研究者
相似试验
尚未招募
4 期
Comparing the efficacy and safety of imeglimin versus sitagliptin as add-ons to metformin in patients not acheiving glycemic control on metformin.CTRI/2024/03/063813Dr. Kriti Kalra
尚未招募
3 期
A Clinical Trial To Compare The Efficacy And Safety Of Imeglimin ( A Novel Anti-Diabetic agent) With Existing Anti-Diabetic Agents In Newly Diagnosed Type 2 Diabetes Patients.CTRI/2023/11/060291Government Medical College, Jammu
尚未招募
3 期
A study to compare efficacy and safety of Imeglimin versus Vildagliptin in type-2 diabetes mellitusCTRI/2023/09/057663Dr Noor Husain
招募中
不适用
Prospective study of the efficacy of imeglimin and metformin against insulin secretion and resistance in patients with type 2 diabetesType 2 diabetesD003924JPRN-jRCTs051220075Hamamoto Yoshiyuki40
尚未招募
4 期
Study of efficacy and side effects of imeglimin as an antidiabetic agent as single drug or as an add on drugCTRI/2024/04/065835Abhinav Garg